Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.76 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015598 | 1.00 | EGFR (0.76) | EGFRMETALKIGF1RKCNH2 | |
| SCHEMBL27075979 | 0.92 | EGFR (0.74) | EGFRMETALKIGF1R | |
| SCHEMBL27076030 | 0.88 | EGFR (0.74) | EGFRMETALKKCNH2 | |
| SCHEMBL21846983 | 0.86 | EGFR (1.00) | EGFRMET | |
| SCHEMBL21846970 | 0.82 | EGFR (1.00) | EGFRMET | |
| SCHEMBL27076117 | 0.82 | ALK (0.65) | EGFRMETALKIGF1RKCNH2 | |
| SCHEMBL27076036 | 0.81 | EGFR (0.74) | EGFRALK | |
| SCHEMBL27076173 | 0.81 | EGFR (0.61) | EGFRMETALKIGF1RKCNH2 | |
| SCHEMBL27075996 | 0.80 | EGFR (0.64) | EGFRMETALK | |
| SCHEMBL29173188 | 0.79 | EGFR (0.61) | EGFRMETALKIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117203199-A | N2-phenylpyrimidine-2, 4-diamine compounds, methods of making and using the same | 毕利吉生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |